| 1. |
|
|
| 2. |
- Kriström, Berit, et al.
(författare)
-
Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature
- 2009
-
Ingår i: Journal of Clinical Endocrinology and Metabolism. - : The Endocrine Society. - 0021-972X .- 1945-7197. ; 94:2, s. 483-490
-
Tidskriftsartikel (refereegranskat)abstract
- CONTEXT: Weight-based GH dosing results in a wide variation in growth response in children with GH deficiency (GHD) or idiopathic short stature (ISS). OBJECTIVE: The hypothesis tested was whether individualized GH doses, based on variation in GH responsiveness estimated by a prediction model, reduced variability in growth response around a set height target compared with a standardized weight-based dose. SETTING: A total of 153 short prepubertal children diagnosed with isolated GHD or ISS (n = 43) and at least 1 SD score (SDS) below midparental height SDS (MPH(SDS)) were included in this 2-yr multicenter study. INTERVENTION: The children were randomized to either a standard (43 microg/kg.d) or individualized (17-100 microg/kg.d) GH dose. MAIN OUTCOME MEASURE: We measured the deviation of height(SDS) from individual MPH(SDS) (diffMPH(SDS)). The primary endpoint was the difference in the range of diffMPH(SDS) between the two groups. RESULTS: The diffMPH(SDS) range was reduced by 32% in the individualized-dose group relative to the standard-dose group (P < 0.003), whereas the mean diffMPH(SDS) was equal: -0.42 +/- 0.46 and -0.48 +/- 0.67, respectively. Gain in height(SDS) 0-2 yr was equal for the GH-deficient and ISS groups: 1.31 +/- 0.47 and 1.36 +/- 0.47, respectively, when ISS was classified on the basis of maximum GH peak on the arginine-insulin tolerance test or 24-h profile. CONCLUSION: Individualized GH doses during catch-up growth significantly reduce the proportion of unexpectedly good and poor responders around a predefined individual growth target and result in equal growth responses in children with GHD and ISS.
|
|
| 3. |
- Akhiani, Aliasghar, 1957, et al.
(författare)
-
Interaction of cholera toxin with three life-cycle stages of Schistosoma mansoni: adult worm, egg and cercaria
- 2007
-
Ingår i: Scand J Immunol. ; 65:1, s. 48-53
-
Tidskriftsartikel (refereegranskat)abstract
- We have previously reported that there is an immunological cross-reactivity between Schistosoma mansoni and cholera toxin (CT). In this study, using an immunofluorescence technique with anti-CT antibody, we provide further evidence for this cross-reactivity by demonstrating an antigen, localized in the tegument of S. mansoni adult worms which is cross-reactive with a CT antigen. Anti-CT antibodies also reacted with structures in S. mansoni cercariae and eggs. Additionally, CT itself was found to bind strongly to the gut of the adult worm, gut cells of cercaria and the egg shell. The binding of CT to the parasite was blocked when parasite sections were incubated with CT which had been incubated with the ganglioside GM1. Lipid extraction and isolation of gangliosides demonstrated the presence of GM1 in adult worms. For further analysis of CT-binding structures, the possible interaction of CT with two major schistosome gut antigens, circulating cathodic antigen (CCA) and circulating anodic antigen (CAA), was studied. We found that CT blocked the binding of anti-CCA antibody to the gut of adult worms and that anti-CCA blocked the binding of CT to the worm gut. These findings indicate that CT binds to CCA present in the gut of the parasite and thus has, in addition to GM1, a second binding specificity.
|
|
| 4. |
- Arvidsson, Sara, et al.
(författare)
-
Intelligenta försäkringar för person- och lastbilar
- 2006
-
Rapport (populärvet., debatt m.m.)abstract
- Within the European Union there are annually about 1 300 000 accidents with physical injuries. Estimates indicate that accident costs add up to €160 billion, corresponding to 2 percent of the Union's GDP. On Sweden's roads alone 400-500 people are killed annualy and thousands are injured. Traffic accidents are, like in most other countries, one of the country's national health problems. Substantial resources are allocated to reduce the number of accidents and their consequences, once an accident occurs. The insurance industry is one part in this. The focus of this report is how insurance companies design their insurance premiums and the possibility to change this design in order to curb accident risks. Our starting point is that modern techniques makes it feasible to link the way in which the premium is calculated to actual behaviour. The fast development of in-vehicle "black box" technology provides prerequisits for observing driver behaviour and in particular speed relative to speed limits. By making speeders pay more than drivers that adhere to speed limits, the insurance system may affect average speed on the road network and consequently also the number and consequences of accidents. The report is made up of three parts. The first presents a review of international experiences of "Pay-as-You-Drive" and "Pay-as-You-Speed" applications. The second reviews technical aspects and the options available when selecting an appropriate solution. A third paper presents a blueprint for the way in which an insurance premium based on "Pay-as-You-Speed" could be designed in order to capture important incentive aspects of the system. It is suggested that the insurance industry should go ahead with the development of these techniques. It is, however, also acknowledged that the incentives of the industry may be insuffient to carry the implementation costs. Since society at large carries much more of the accident costs than the industry itself, this provides prima facie motive for government intervention in order to avoid a market failure. It is argued that the costs for establishing an open technical platform in vehicles and to organise the collection of data may be small relative to the potential benefits of the system.
|
|
| 5. |
- Arvidsson, Sara, et al.
(författare)
-
Smarta försäkringar ger färre trafikolyckor
- 2006
-
Ingår i: Ekonomisk debatt. - 0345-2646. ; :6, s. 6-17
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- För att uppnå högt ställda trafiksäkerhetsmål måste trafikanterna förmås att sänka hastigheten. Artikeln argumenterar för att smarta försäkringspremier som belönar dem som kör trafiksäkert kan bli ett viktigt instrument för detta ändamål. Försäkringsbolagen blir därmed samhällets agenter i kampen för att successivt minska antalet olyckor.
|
|
| 6. |
|
|
| 7. |
- Berglin-Enquist, Ida, et al.
(författare)
-
Murine models of acute neuronopathic Gaucher disease
- 2007
-
Ingår i: Proceedings of the National Academy of Sciences of the United States of America. - : Proceedings of the National Academy of Sciences. - 0027-8424 .- 1091-6490. ; 104:44, s. 17483-17488
-
Tidskriftsartikel (refereegranskat)abstract
- Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder caused by mutations in the glucosidase, beta, acid (GBA) gene that encodes the lysosomal enzyme glucosylceramidase (GCase). GCase deficiency leads to characteristic visceral pathology and, in some patients, lethal neurological manifestations. Here, we report the generation of mouse models with the severe neuronopathic form of GD. To circumvent the lethal skin phenotype observed in several of the previous GCase-deficient animals, we genetically engineered a mouse model with strong reduction in GCase activity in all tissues except the skin. These mice exhibit rapid motor dysfunction associated with severe neurodegeneration and apoptotic cell death within the brain, reminiscent of neuronopathic GD. In addition, we have created a second mouse model, in which GCase deficiency is restricted to neural and glial cell progenitors and progeny. These mice develop similar pathology as the first mouse model, but with a delayed onset and slower disease progression, which indicates that GCase deficiency within microglial cells that are of hematopoietic origin is not the primary determinant of the CNS pathology. These findings also demonstrate that normal microglial cells cannot rescue this neurodegenerative disease. These mouse models have significant implications for the development of therapy for patients with neuronopathic GD.
|
|
| 8. |
- Berglin-Enquist, Ida, et al.
(författare)
-
Successful Low-Risk Hematopoietic Cell Therapy in a Mouse Model of Type 1 Gaucher Disease
- 2009
-
Ingår i: Stem Cells. - : Oxford University Press (OUP). - 1549-4918 .- 1066-5099. ; 27:3, s. 744-752
-
Tidskriftsartikel (refereegranskat)abstract
- Hematopoietic stem cell-based gene therapy offers the possibility of permanent correction for genetic disorders of the hematopoietic system. However, optimization of present protocols is required before gene therapy can be safely applied as general treatment of genetic diseases. In this study we have used a mouse model of type 1 Gaucher disease (GD) to demonstrate the feasibility of a low-risk conditioning regimen instead of standard radiation, which is associated with severe adverse effects. We first wanted to establish what level of engraftment and glucosylceramidase (GCase) activity is required to correct the pathology of the type 1 GD mouse. Our results demonstrate that a median wild-type (WT) cell engraftment of 7%, corresponding to GCase activity levels above 10 nmoles/hour and mg protein, was sufficient to reverse pathology in bone marrow and spleen in the GD mouse. Moreover, we applied nonmyeloablative doses of busulfan as a pretransplant conditioning regimen and show that even WT cell engraftment in the range of 1%-10% can confer a beneficial therapeutical outcome in this disease model. Taken together, our data provide encouraging evidence for the possibility of developing safe and efficient conditioning protocols for diseases that require only a low level of normal or gene-corrected cells for a permanent and beneficial therapeutic outcome. STEM CELLS 2009; 27: 744-752
|
|
| 9. |
- Berglin-Enquist, Ida, et al.
(författare)
-
Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease.
- 2008
-
Ingår i: - : Mary Ann Liebert Inc. ; , s. 1189-1190
-
Konferensbidrag (refereegranskat)abstract
- Hematopoietic stem cell (HSC) based gene therapy offers the possibility of permanent correction for genetic disorders of the hematopoietic system. However, optimization of present protocols is required before gene therapy can be safely applied as general treatment of genetic diseases. In this study we have used a mouse model of type 1 Gaucher disease (GD) to demonstrate the feasibility of a low-risk conditioning regimen instead of standard radiation, which is associated with severe adverse effects. We first wanted to establish what level of engraftment and glucosylceramidase (GCase) activity is required to correct the pathology of the type 1 GD mouse. Our results demonstrate that a median WT cell engraftment of 7 % corresponding to GCase activity levels above 10 nmol/hr and mg protein was sufficient to reverse pathology within bone marrow (BM) and spleen in the GD mouse. Moreover, we applied non-myeloablative doses of busulphan as a pretransplant conditioning regimen and show that even WT cell engraftment in the range of 1-10% can confer a beneficial therapeutical outcome in this disease model. Taken together, our data provide encouraging evidence for the possibility to develop safe and efficient conditioning protocols for diseases that only require a low level of normal or gene corrected cells for a permanent and beneficial therapeutic outcome. ______________________________________________________________________________ Author contributions: I.B.E.: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing; E.N.: Collection of data, data analysis and interpretation; J.-E.M.: Collection and assembly of data, data analysis and interpretation; M.E.: Collection and assembly of data, data analysis and interpretation; J.R.: Data analysis and interpretation, manuscript writing; S.K.: Conception and design, financial support, data analysis and interpretation, manuscript writing, final approval of manuscript.
|
|
| 10. |
|
|
